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Objectives Inducible costimulator (ICOS) and its ligand (ICOSL) regulate T and B cell responses. 
Glucose-6-phosphate isomerase (G6PI)-induced arthritis requires T and B lymphocytes. It was 
hypothesised that blocking ICOS/ICOSL interactions ameliorates G6PI-induced arthritis and reduces 
G6PI-specific B and T lymphocyte responses.  
Methods DBA/1 mice were injected with a blocking, non-depleting anti-ICOSL monoclonal antibodies 
(mAbs) during the induction or effector phase of G6PI-induced arthritis. G6PI-specific antibody 
responses were measured by ELISA. G6PI-specific T helper (Th) cell responses were assayed by 
polychromatic flow cytometry.  
Results Transient blockade of ICOS/ICOSL interactions profoundly reduced the severity of G6PI-
induced arthritis. ELISA and proliferation assays showed no clear ex vivo correlates of protection. 
Polychromatic flow cytometry revealed two major findings: the absolute number of G6PI-specific Th 
cells was markedly diminished in secondary lymphatic organs from mice with blocked ICOS/ICOSL 
interactions. Within the pool of G6PI-specific Th cells the frequency of interleukin 17 (IL17), interferon 
γ or tumour necrosis factor α producers or polyfunctional Th cells (expressing two or more of these 
cytokines) was higher in treated than in control mice.  
Conclusions ICOS costimulation is not mandatory for the differentiation of Th1 or Th17 cells. Instead, 
the lack of ICOS costimulation results in reduced survival of G6PI-specific Th cells irrespective of their 
functional differentiation. This study demonstrates that a thorough examination of the quantity and the 
quality of antigen-specific immune responses is useful to determine ex vivo correlates of efficacy for 




Clinical and experimental data suggest that rheumatoid arthritis (RA) is an autoimmune disease and 
recent clinical trials indicate a role for T and B lymphocytes.1 2 In murine models of RA, immunisations 
with cartilage constituents or systemic alterations in the immune system can induce arthritis.  
Immunisation of DBA/1 mice with the ubiquitous autoantigen glucose-6-phosphate isomerase (G6PI) 
or a self-peptide derived from the G6PI sequence induces symmetric polyarthritis with a rapid onset 
and a high incidence,3 4 Importantly, B cells and T cells are critically required for the disease, 
demonstrated by the inability to induce the disease in B cell-deficient mice and furthermore by the 
preventive and therapeutic effectiveness of CD4 cell depletion.3 5 Severity of G6PI-induced arthritis 
  
can be inhibited by blockade of tumour necrosis factor α (TNFα),3 interleukin 17 (IL17)6 and injection 
of cytotoxic T lymphocyte antigen 4 (CTLA4) Ig.7 
Interactions between inducible costimulator (ICOS) (CD278) and its ligand (ICOSL) (CD275) regulate 
adaptive immune responses. ICOS is expressed at low levels by resting T cells, strongly upregulated 
upon activation8 and highly expressed on T follicular helper (TFH) cells within germinal centres.9 
ICOSL is widely and constitutively expressed in lymphoid tissue and can be induced in non-lymphoid 
tissues under inflammatory conditions.10 11 Blockade of ICOS/ICOSL interactions using monoclonal 
antibodies (mAbs) against ICOSL has been shown to be beneficial in collagen-induced arthritis 
(CIA)12 13 and murine models of lupus.13 14 In experimental autoimmune encephalomyelitis (EAE), 
however, treatment during the induction phase exacerbated the disease, whereas later treatment 
blocked the disease15 and ICOS-deficient mice are more susceptible to EAE than wild-type mice.16 
17 The unpredictable outcome of ICOS blockade in vivo together with the pathogenetic relevance of T 
helper (Th) cells and T/B interaction in G6PI-induced arthritis prompted us to investigate the role of 
ICOS/ICOSL interaction in G6PI-induced arthritis.  
 
 
Materials and methods 
 
Mice and induction of arthritis 
DBA/1 mice (6–12 weeks old) were immunised subcutaneously at the base of the tail with 400 µg 
recombinant human G6PI,3 emulsified in 100 µl complete Freund's adjuvant (CFA; Sigma-Aldrich, 
Taufkirchen, Germany). Animals were scored for clinical signs of inflammation (redness, swelling) on a 
0–3-point scale for each paw, giving a total maximum score of 12. Histopathological assessment was 
performed as described previously3 by a pathologist (LM) who was blinded with respect to the 
experimental groups. Mice were treated three times with 100 µg anti-ICOSL antibody (MIL-5733) at 
the indicated time points after immunisation. MIL-5733 is a non-depleting, blocking mAb (see 




Titres of G6PI-specific antibodies were measured by ELISA as previously described.3 The titre was 




Single cell suspensions from draining lymph nodes were prepared at day 9 after immunisation and 
cultured with 10 µg/ml G6PI for 72 h or left unstimulated. [
3
H]-thymidine (1 µCi) per well was added for 
the last 18 h. Incorporated radioactivity was measured using a γ scintillation counter (Perkin Elmer, 
Rodgau-Jügesheim, Germany).  
 
Cytokine ELISA 
Lymph node cells were cultured with 10 µg/ml G6PI for 48 h. Interferon γ (IFNγ) and IL17 content in 
culture supernatants was measured by sandwich ELISA using matched antibody pairs from BD or an 







Cells from draining lymph nodes (1×10
7
 cells/ml) were cultured for 6 h with 20 µg/ml G6PI or left 
unstimulated. For the last 4 h, Brefeldin A (Sigma) at 5 µg/ml was added to all samples. Subsequently 
cells were washed and incubated with the fixable amine-reactive Aqua viability stain (Invitrogen) AU: 
please give address details for Invitrogen, eBiosciences and Miltenyi according to manufacturer's 
instructions. After fixation (2% paraformaldehyde) and permeabilisation with 0.5% Saponin/0.5% 
bovine serum albumin/0.02% NaN3 in phosphate buffered saline, non-specific binding of antibodies 
was blocked by preincubation of the cells with anti-CD16/32 (2.4G2) and rat IgG, followed by staining 
with fluorochrome-conjugated mAbs against CD4, IFNγ, TNFα, IL17, IL10 (eBiosciences) and CD154 
(Miltenyi Biotech). Early expression of CD154 is highly dependant on T cell receptor (TCR) stimulation 
and is used to identify Ag-specific Th cells.19,–,21 2.5 million events were acquired using a BD LSRII 
flow cytometer. Data were analysed using FlowJo 8.1.1 (Tree Star, Ashland, Oregon, USA). Gates for 
CD154 were set using unstimulated control samples and gates for cytokine
+
 cells were set using 
fluorescence –1 controls for the respective cytokine.  
 
Statistics 
Data were analysed using the non-parametric Mann–Whitney U test with SPSS 15.0 (SPSS, Chicago, 
Illinois, USA) unless otherwise indicated. Graphs were generated using SigmaPlot 10.0 (Systat 
Software, Chicago, Illinois, USA). For analysis of boolean-gated cells, data were exported from FlowJo 
and analysed using PESTLE 1.5.4 and SPICE 4.1.6 software suites (kindly provided by Dr M 
Roederer, Vaccine Research Center, NIAID/NIH, Bethesda, Maryland, USA). Data are presented as 




Blockade of ICOS/ICOSL interactions ameliorates G6PI-induced arthritis 
G6PI-immunised DBA/1 mice were left untreated or injected with 100 µg anti-ICOSL mAb (MIL-5733, 
a blocking and non-depleting mAb; see supplementary figure 1 for details) either at days 2, 4 and 6 or 
at days 13, 15 and 17 after immunisation. Mice treated early developed profoundly less severe arthritis 
as judged by clinical and histological parameters (figure 1A–C). Treatment at the peak of clinical 
disease (days 13, 15 and 17) resulted in only marginally reduced clinical arthritis severity (figure 1A) 
suggesting that ICOS/ICOSL interactions are critical for the induction but less important for the 
perpetuation of G6PI-induced arthritis.  
 
Blockade of ICOS/ICOSL interactions does not alter G6PI-specific Ig production 
B lymphocytes and FcγR
+
 effector cells are central elements in the pathogenesis of G6PI-induced 
arthritis.3 5 Since ICOS/ICOSL interactions are crucial for germinal centre formation, antibody 
production and isotype switching, we investigated whether the preventive effect of the anti-ICOSL mAb 
treatment was due to a reduced production of anti-G6PI antibodies. ELISAs for G6PI-specific IgM, 
IgG1, IgG2a, IgG2b and IgA did not reveal statistically significant differences between treated and 
control mice 9 days after immunisation (figure 2A) or at later time points (data not shown). Therefore, 
the preventive effect of short-term ICOS blockade is not mediated via inhibition or alteration of anti-
G6PI antibody production.  
  
Impaired proliferation but unaltered cytokine production in lymph node cells from anti-ICOSL-
treated mice 
Next, we investigated if blockade of ICOS costimulation influences the G6PI-specific T cell response. 
At 9 days after G6PI immunisation total lymph node cellularity and T cell numbers were similar in anti-
ICOSL mAb-treated and control mice (figure 2B and data not shown). Using bulk assays of G6PI-
restimulated lymph node cells, we found that proliferation was reduced in anti-ICOSL mAb-treated 
mice (figure 2C). The concentrations of IFNγ and IL17 in culture supernatants of these restimulated 
lymph node cells however were only slightly lower in treated mice as compared with controls (figure 
2D). Taken together, these analyses employing whole organ cultures failed to reveal a clear cut ex 
vivo correlate for the clinical effects of ICOS blockade.  
 
Reduced number but unimpaired Th1/Th17 differentiation of G6PI-specific Th cells in anti-
ICOSL-treated mice 
We next analysed the G6PI-specific Th cell response by polychromatic flow cytometry. Cells from 
draining lymph nodes were briefly restimulated with G6PI. G6PI-specific T cells were identified by 
staining for CD4 and CD154 (see supplementary figures 2 and 3A for details) and further analysed for 
cytokine production as described in the Materials and methods section. The total number of CD4 T 
cells was not reduced in the treated mice (data not shown). In contrast, the frequency of G6PI-specific 
T cells among all CD4 T cells was significantly reduced in mice treated with anti-ICOSL mAb (figure 
3A; 0.52±0.07% vs 1.32±0.16% in control mice, mean±SEM, p<0.008). Therefore, the anti-ICOSL-
treated mice harboured only approximately half the number of G6PI-specific Th cells than the control 
mice. To assess the functional differentiation of the G6PI-specific Th cells, we investigated their 
expression of IFNγ, TNFα, IL17 and IL10. The pattern of cytokine expression of G6PI-specific T cells 
was roughly similar between control and anti-ICOSL-treated mice with approximately 22% versus 26% 
TNFα producing, 19% versus 25% IL17 producing and 9% versus 13% IFNγ producing cells in the 
controls and the anti-ICOSL-treated group, respectively (figure 3B). IL10-producing G6PI-specific T 
cells were undetectable in both groups of mice (data not shown). Thus, although the number of G6PI-
specific Th cells was strikingly reduced in anti-ICOSL-treated mice, differentiation towards Th1 or Th17 
phenotypes was unimpaired or even slightly enhanced. In treated and control mice the majority of 
IFNγ-producing G6PI-specific Th cells also produced TNFα (figure 3B, left panel). Similarly, about half 
of the IL17 producing cells coproduced TNFα (figure 3B, middle panel). Remarkably, approximately 
50% of the IFNγ producers coproduced IL17 (figure 3B, right panel).  
For a more detailed analysis of Th cell cytokine coexpression, we used a boolean combination of 
gates22 to identify among the G6PI-specific CD4CD154 cells those that produced either one of the 
analysed cytokines alone, any possible combination of two cytokines, or all three cytokines. Thus, 
seven different possible subsets of cytokine-expressing cells can be identified (figure 3C and 
supplementary figure 3B). Due to their lower number of G6PI-specific Th cells (figure 3A), the treated 
mice also harboured fewer G6PI-specific cytokine producers than the controls (figure 3C). The overall 
pattern of cytokine coproduction differed little between the two groups of mice. Therefore, these data 
reveal that ICOS costimulation is not critically required for T cell differentiation into specific effector 
subsets, but rather regulates the magnitude of a T cell response.  






) were very infrequent in either group of mice. 
Boolean gating revealed that the vast majority of IFNγ and IL17 coexpressing cells were triple positive, 






, figure 3C). This could not have been 
detected from the two-dimensional dot plots shown in figure 3B.  
 
ICOS costimulation is not essential for early proliferation of antigen-specific T cells 
Having established that the blockade of ICOS costimulation strongly reduced the number of G6PI-
specific T cells (figure 3A), but did not impair the functional differentiation of the G6PI-specific Th cells, 
we next aimed to investigate whether this reduced magnitude of the G6PI-specific Th cell response 
was mediated by decreased proliferation. Currently available techniques prohibit the tracking of G6PI-
specific Th cells in vivo. Therefore, we adoptively transferred carboxyfluorescein succinimidyl ester 
(CFSE)-labelled ovalbumin (OVA)323–339/I-A
b
-specific T cells from TCR-transgenic OT-II mice into 
  
C57BL/6 recipients, which were subsequently immunised with OVA and treated with anti-ICOSL mAb. 
As shown in figure 4A, 3 days after transfer there was no difference in the percentage of transgenic T 
cells among all CD4 T cells between anti-ICOSL-treated mice and controls, whereas by day 7 the 
number of transgenic T cells in treated mice was reduced by half. This reduction of antigen-specific T 
cells could not be attributed to arrested proliferation because at day 3 the frequency of OT-II cells in 
the CD4 compartment in every generation was similar in both groups of mice (figure 4B). By day 7, 
there was still a low but similar frequency of cells in the first five generations in both groups. In 
generations 6 and later, however, there were significantly fewer cells in the anti-ICOSL mAb-treated 
group, compared to controls. Our data using anti-ICOSL mAb therefore confirm and extend our 
previous results using ICOSL-deficient mice as recipients of TCR transgenic cells and thereby 
demonstrate that our treatment approach effectively blocked ICOS costimulation.8 Of note, since the 
OVA-specific T cells were identified by their expression of the transgenic TCR chains this also 
excludes the possibility that the reduced number of G6PI-specific T cells, detected by CD154 
expression, was due to a defective CD154 upregulation in mice treated with anti-ICOSL.  
We also examined the cytokine production of the transgenic T cells in this adoptive transfer system. 
As shown in figure 4C, there was no difference in the expression of IFNγ, TNFα and IL17 between 
both groups at day 3. At day 7, however, we found a higher proportion of cells producing either 
cytokine in the antigen-specific T cell compartment of the mice treated with anti-ICOSL mAb (figure 
4C). This confirms our findings in the arthritis model that ICOS costimulation is not pivotal for the 
acquisition of particular T cell effector functions. The net effect of the greatly diminished numbers of 
antigen-specific T cells with similar or even slightly enhanced proportions of cytokine producing cells is 
a significant reduction of antigen-specific cells producing effector cytokines in the mice treated with the 




In this study, we show that a brief treatment with a blocking anti-ICOSL antibody profoundly reduces 
the severity of G6PI-induced arthritis. Protection from arthritis was associated with a sharply reduced 
number of G6PI-specific Th cells. Although surprising, given the large role of ICOS/ICOSL interactions 
in humoral immune responses, we did not find reduced serum concentrations of anti-G6PI IgM, IgG 
and IgA antibodies in anti-ICOSL-treated mice. However, our findings are in line with earlier studies, 
which demonstrated that the reduced production of IgG1 and IgG2a antibodies in ICOS-deficient mice 
could be overcome by using CFA as adjuvant.23 In studies on CIA, ICOSL blockade was associated 
with an ameliorated course of arthritis and a reduction in collagen type II (CII)-specific IgG1, IgG2a 
and IgG2b antibodies.12 13 One important difference between the CIA model and G6PI-induced 
arthritis investigated in our study is the much earlier onset of G6PI-induced arthritis. The reduced 
serum titres of anti-CII antibodies in the studies on ICOSL blockade in CIA12 13 were detected 
between day 28 and day 43 after the primary immunisation, that is, much later than in our 
investigation. Hence, it remains hypothetically possible that a reduction of G6PI-specific Igs in the 
treated mice would be detectable at later time points. However, approximately 30 days after 
immunisation G6PI-induced arthritis is usually resolved (figure 1 and Schubert et al3), further 
emphasising the pathogenetic differences between G6PI-induced arthritis and CIA. Consequentially, 
the mechanisms mediating the protective effects of ICOS blockade may differ between G6PI-induced 
arthritis and CIA.  
Another distinguishing feature of G6PI-induced arthritis is that Th cells are obligatory in the induction 
and the effector phase of the disease. CD4 depletion cures established G6PI-induced arthritis in 
DBA/1 mice.3 Given this prominent role of Th cells in G6PI-induced arthritis, we used CD154 
expression to identify G6PI-specific Th cells and examined their cytokine production directly. CD4 T 
cells rapidly and transiently upregulate expression of CD154 upon TCR stimulation.19 20 CD154 
expression is therefore highly indicative of antigen-specific CD4 T cell stimulation during the 6 h of in 
vitro culture (supplementary figure 2 and references by Chattopadhyay et al, Frentsch et al, Mittrücker 
et al, Huaman et al, Gaucher et al and Tokoyoda et al19 20 24,–,27).  
In mice treated with anti-ICOSL mAb, the most prominent effect on the pathogenic T cell response 
was the markedly reduced number of G6PI-specific T cells. This finding was not peculiar to the G6PI-
induced arthritis model but was also confirmed for OVA-specific T cells in the OT-II TCR transgenic T 
  
cell adoptive transfer model. Our data presented here, support our earlier work and strongly suggest 
that ICOS costimulation is not critical for early proliferation (ie, first five generations). Instead, the most 
likely explanation for the reduced number of G6PI-specific or OT-II cells in the absence of ICOS 
costimulation is reduced survival after unaffected priming and early proliferation. Thus, a reduced 
G6PI-specific T cell response due to decreased survival of these cells is the most likely mechanism for 
the clinical effect of the treatment on arthritis development and explains why our short course 
treatment had long lasting effects. Additionally, since the peak of the T cell response precedes the 
onset of clinical disease in G6PI-induced arthritis3 this explains why the late treatment with anti-ICOSL 
had very little effect on arthritis severity.  
The published data as to whether ICOS specifically supports the differentiation of a particular Th 
subset is highly contradictory.16 17 28,–,30 Most reports were based on observations of reduced 
expression of signature cytokines after blockade of ICOS costimulation or in ICOS-deficient mice. 
Several groups, including ours, have already shown in earlier work that ICOS expression is not linked 
to the expression of particular cytokines.8 31 32 Bauquet et al recently reported that Th17 
development was unimpaired in ICOS-deficient mice. However, after several days of in vitro culture in 
the presence of cytokines including IL23, the frequency of IL17-producing TFH cells was lower in ICOS-
deficient mice than in wild-type controls.17 Our data presented here demonstrate that ICOS 
costimulation is critically required for the maintenance of the antigen-specific Th cell pool in vivo but 
not mandatory for Th1/Th17 differentiation. Therefore, our data are compatible with the idea that 
earlier reports on reduced expression of Th1 or Th17 cytokines in the absence of ICOS costimulation 
reflect the lower absolute number of antigen-specific T cells rather than a diminished intrinsic 
propensity of these cells to differentiate into particular Th effector cell subsets. Importantly, these 
conclusions could be drawn only from complex simultaneous assessment of the number and cytokine 
production of antigen-specific T cells using polychromatic flow cytometry. Further illustrating this point 
is the fact that the reduced absolute number of G6PI-specific cytokine producing Th cells was not 
detected by cytokine measurements in culture supernatants by ELISA. A number of variables including 
cytokine production CD4 T cells which are not specific for G6PI (ie, bystander activation), cytokine 
production by cells which are not CD4 T cells and the consumption of cytokines released into the 
culture, could explain the discrepancy between the flow cytometric analyses of cytokine expression by 
G6PI-specific T cells and the cytokine ELISA.  
A substantial proportion of the G6PI-specific Th cells coexpressed combinations of two or even three 
cytokines simultaneously and was thus polyfunctional. The frequency of such polyfunctional T cells 
rather than the total numbers of IFNγ producing cells has been associated with the ability to control or 
prevent chronic infections in a series of recent studies in mice and man.21 22 26 33,–,39 The 
relevance of polyfunctional T cells for protective or pathogenic T cell responses cannot be assessed 
directly with current technologies, which do not permit the isolation of distinct viable cell populations 
producing different combinations of cytokines. Still, our data suggest that such polyfunctional T cells 
might be also relevant in autoimmunity. Similar to the infection studies21 22 26 33,–,39 we also noted 
a higher per cell cytokine production of cells producing combinations of two or all three cytokines 
examined (data not shown). Consequently, a small reduction of such polyfunctional T cells could have 
an overproportional effect compared to reductions of cells that produce only one single cytokine. As 
exemplified in this report, less complex assessment of T cell functions harbours significant risks of 
underestimation or overestimation of alterations in the magnitude and quality of antigen-specific Th 
cell response. Therefore polychromatic flow cytometry could become one useful tool for the evaluation 
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Figure 1  Anti-ICOSL treatment prevents G6PI-induced arthritis. A. DBA/1 mice were immunised with 
400 µg G6PI in complete Freund's adjuvant and treated with 100 µg anti-ICOSL monoclonal antibody 
(mAb) MIL-5733 either at days 2, 4 and 6 (circles) or at days 13, 15 and 17 after immunisation 
(squares). Control mice (inverted triangles) were immunised but otherwise left untreated. Clinical 
arthritis severity was scored at the indicated time points on a 0–3 scale for each limb, giving a total 
maximum score of 12. Each group consists of at least five mice and the data shown are representative 
for two separate experiments. B. Severe synovitis in control mice (upper panel) with inflammatory 
infiltrates (black arrows), pannus formation with abundant activated fibroblasts (white arrows), severe 
destruction of bone and cartilage (stars) and extension of the inflammation into the adjacent skeletal 
muscle (circle). Normal joint architecture and absence of inflammation in mice treated with anti-ICOSL 
mAb at days 2, 4 and 6 (lower panel). The cartilage surfaces are smooth and intact (stars), the 
synovial lining is not enlarged (arrows) and no inflammatory cells can be detected. Representative 
photomicrographs of joint sections prepared 40 days after immunisation with 400 µg G6PI (H & E 
staining; original magnification ×50 (left) or ×200 (middle and right), respectively). C. Semiquantitative 
scoring of the histopathological changes in the affected paws showed significant reduction of 
histological arthritis severity by anti-ICOSL treatment at days 2, 4 and 6 (n=5, open bars) compared to 
control mice (n=5, filled bars, p<0.05). G6PI, glucose-6-phosphate isomerase; ICOS, inducible 





Figure 1 (continued) 
  
Figure 2  Effects of ICOS blockade on G6PI-specific immunoglobulin production, proliferation and 
cytokine production. A. DBA/1 mice were immunised with 400 µg G6PI and left untreated (filled bars) 
or were treated with 100 µg anti-ICOSL monoclonal antibody (mAb) at days 2, 4 and 6 after 
immunisation (open bars). Sera were obtained at day 9 after immunisation and titres of G6PI-specific 
immunoglobulins of the indicated isotypes were measured by ELISA. Data shown are from one 
representative experiment (n=five mice per group). B. Single cell suspensions were prepared from 
draining lymph nodes from anti-ICOSL mAb-treated mice (open bars) or controls (filled bars) at day 9 
after immunisation. Lymph nodes from anti-ICOSL mAb-treated mice and controls yielded equal 
numbers of cells. C,D. Lymph node cells were restimulated in vitro with G6PI and proliferation was 
measured using [
3
H]-thymidine incorporation for the last 16 h of a 72 h restimulation period. Culture 
supernatants were collected after 48 h and concentrations of interferon γ and interleukin 17 were 
determined using ELISA. Data are representative for two independent experiments with three to five 











Figure 3 Multiparameter flow cytometry reveals differences in the number and differentiation of G6PI-
specific T cells. A. Single cell suspensions were prepared from draining lymph nodes from anti-ICOSL 
monoclonal antibody (mAb)-treated mice or controls at day 9 after immunisation. Cells were cultured in 
vitro with G6PI for 6 h and stained for with mAbs against CD4, CD154 and cytokines as described in 
the Materials and methods section. Gates were set as exemplified in supplementary figure 2A. 
Upregulation of CD154 in G6PI-stimulated (right) vs unstimulated samples (left) in control (upper row) 
and anti-ICOSL-treated mice (lower row). Numbers indicate the frequencies of G6PI-specific CD154 T 
cells among all CD4 cells. B. Dot plots show the expression of IFNγ vs TNFα (left), IFNγ vs IL17 
(middle) and TNFα vs IL17 in control (upper row) and anti-ICOSL-treated mice (lower row). Events in 
dot plots contain only G6PI-specific (CD154 cells; indicated by arrows). The frequency of cytokine 
expressing cells among CD154 cells is given in each quadrant. Data depicted in A and B are 
concatenated data files from five mice per group. C. G6PI-specific T cells producing one, a 
combination of two or all three cytokines examined were identified using boolean gating 
(supplementary figure 2B). Total numbers of G6PI-specific cytokine producing T cells per mouse in 
control (inverted triangles) and anti-ICOSL-treated mice (circles). Data in A–C are from five mice per 
group, *p<0.05, Wilcoxon rank sum test. G6PI, glucose-6-phosphate isomerase; ICOS, inducible 






Figure 4 ICOS blockade has no impact on early proliferation and effector cell differentiation in an 
adoptive transfer model. A. Carboxyfluorescein succinimidyl ester (CFSE)-labelled CD4 T cells (2×10
6
) 
from OT-II mice were adoptively transferred into C57BL/6 mice. Then, 1 day later, recipients were 
immunised with ovalbumin (OVA)323–339. Mice were treated with anti-ICOSL monoclonal antibody 
(mAb) at day 0, 2 and 4 relative to immunisation. Numbers of transferred transgenic T cells (TCR Vα2 
and Vβ5.1/5.2 positive CD4 cells) among all CD4 T cells in draining lymph nodes 3 (left panel) and 7 
(right panel) days after immunisation. B. Analysis of proliferation by CFSE dilution. Frequency of 
transgenic T cells among total CD4 cells in each division generation is shown for day 3 and day 7. 
(n=4 per group, *p<0.05). C. Production of interferon γ, tumour necrosis factor α and interleukin17 by 
TCR transgenic T cells adoptively transferred into anti-ICOSL mAb-treated or control mice at day 3 
(upper panel) or day 7 (lower panel). ICOS, inducible costimulator; ICOSL, ICOS ligand, TCR, T cell 
receptor.  
